Live Analyst Rating Changes 2091 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Evans
KEPL
David Evans
Kepler Capital
Wall Street Analyst
★★★☆☆
#1007
on 13Foresight · ranked by our own returns
62%
Success Rate
+9.5%
Average Return
5 of 8 calls profitable · +0.2% vs benchmark
📈 Across the calls we could measure, roughly 62% of David Evans's ratings turned a profit when each position was held for 1 year — averaging +9.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

46 Buy 19 Hold 0 Sell
David's Stock Coverage 36 ratings · 2026-06-23
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
GB:0QIU
Novo Nordisk
 May 22, 2026 HOLD Hold
+40.1% avg upside
28 analysts
$290.00
0.47% Downside
 ·
CH:NOVN
Novartis AG
 May 08, 2026 BUY Buy
-10.8% avg upside
30 analysts
$135.00
12.21% Upside
 ·
DE:MRK
Merck KGaA
 May 01, 2026 BUY Strong Buy
+2.1% avg upside
32 analysts
$152.00
14.19% Upside
 ·
GB:GSK
GlaxoSmithKline
 Apr 29, 2026 HOLD Hold
-2.6% avg upside
25 analysts
$1500.00
22.08% Downside
 ·
GB:AZN
AstraZeneca
 Apr 29, 2026 HOLD Strong Buy
+11.7% avg upside
26 analysts
$11300.00
14.90% Downside
 ·
CH:ROP
Roche Holding AG
 Apr 23, 2026 BUY Strong Buy
+3.5% avg upside
23 analysts
$415.00
30.32% Upside
 ·
GB:0NZT
UCB SA
 Mar 11, 2026 HOLD Buy
-13.3% avg upside
19 analysts
$260.00
4.20% Upside
 ·
FR:SAN
Sanofi
 Jan 30, 2025 HOLD Strong Buy
+35.8% avg upside
30 analysts
$92.00
26.82% Upside
 ·
CH:ALC
Alcon
 Aug 21, 2024 SELL Buy
+34.6% avg upside
35 analysts
$62.00
17.40% Upside
 ·
FR:EAPI
Euroapi SA
 Mar 08, 2023 BUY Buy
+551.3% avg upside
5 analysts
$17.00
1288.91% Upside
 ·
GB:0G99
Oxurion NV
 Jul 07, 2021 HOLD Hold
+962.2% avg upside
2 analysts
$2.90
962.18% Upside
 ·
FR:VIRP
Virbac SA
 Jul 07, 2021 HOLD Buy
+6.0% avg upside
3 analysts
$270.00
20.19% Downside
 ·
FR:OSE
OSE Immunotherapeutics SA
 Jul 07, 2021 BUY Strong Buy
+234.8% avg upside
4 analysts
$16.80
391.52% Upside
 ·
CH:BSLN
Basilea Pharmaceutica
 Jul 07, 2021 BUY Strong Buy
+43.4% avg upside
6 analysts
$67.00
31.54% Upside
 ·
FR:ALQGC
Quantum Genomics Societe Anonyme
 Jul 07, 2021 BUY Strong Buy
+11966.6% avg upside
1 analyst
$8.70
11966.56% Upside
 ·
IPHA
Innate Pharma
 Jul 07, 2021 BUY Strong Buy
+261.0% avg upside
10 analysts
$5.71
215.72% Upside
 -15.5%
NBTX
Nanobiotix
 Jul 07, 2021 BUY Strong Buy
-7.0% avg upside
5 analysts
$29.71
15.75% Downside
 -76.1%
DE:FYB
Formycon AG
 Jul 07, 2021 HOLD Strong Buy
+154.7% avg upside
5 analysts
$65.00
231.62% Upside
 ·
FR:ALGAE
Fermentalg SA
 Jul 07, 2021 HOLD Hold
+526.2% avg upside
1 analyst
$3.00
526.24% Upside
 ·
FR:TNG
Transgene
 Jul 07, 2021 BUY Strong Buy
+462.2% avg upside
1 analyst
$4.20
462.22% Upside
 ·
GRFS
Grifols SA
 Jul 07, 2021 HOLD Hold
+242.7% avg upside
12 analysts
$27.66
279.95% Upside
 -34.3%
LKFT
Lakefront Biotherapeutics
 Jul 07, 2021 HOLD Hold
+266.6% avg upside
24 analysts
$90.28
211.97% Upside
 ·
ARGX
Argenx Se
 Jul 07, 2021 HOLD Strong Buy
-17.7% avg upside
46 analysts
$251.41
72.10% Downside
 +17.7%
FR:ABVX
Abivax SA
 Jul 07, 2021 BUY Strong Buy
-63.9% avg upside
3 analysts
$55.00
35.85% Downside
 ·
ES:ALM
Almirall
 Jul 07, 2021 BUY Buy
+19.4% avg upside
5 analysts
$15.40
37.65% Upside
 ·
GB:0R55
Bone Therapeutics
 Jul 07, 2021 BUY Strong Buy
+259899.9% avg upside
1 analyst
$5.20
259899.95% Upside
 ·
FR:DBV
DBV Technologies
 Jul 07, 2021 HOLD Sell
+91.8% avg upside
3 analysts
$9.00
223.58% Upside
 ·
FR:ALCOX
Nicox SA
 Jul 07, 2021 BUY Buy
+1630.4% avg upside
5 analysts
$10.00
2552.50% Upside
 ·
FR:ALVIO
Valerio Therapeutics
 Jul 07, 2021 BUY Buy
+135.0% avg upside
3 analysts
$1.00
399.96% Upside
 ·
FR:IPN
Ipsen
 Jun 03, 2021 HOLD Buy
-21.9% avg upside
17 analysts
$79.00
49.79% Downside
 ·
DE:BAYN
Bayer
 Mar 03, 2021 BUY Strong Buy
+33.2% avg upside
28 analysts
$62.00
62.41% Upside
 ·
DE:93Z
Marinomed Biotech AG
 Nov 10, 2020 HOLD Hold
+1115.4% avg upside
1 analyst
$110.00
1115.40% Upside
 ·
VALN
Valneva
 Nov 10, 2020 BUY Buy
+108.7% avg upside
5 analysts
$6.86
28.12% Upside
 +90.3%
BPTSY
Biophytis
 Nov 10, 2020 SELL Sell
+23.4% avg upside
2 analysts
$0.31
23.43% Upside
 +61.9%
BAYRY
Bayer
 Oct 08, 2020 BUY Buy
+283.7% avg upside
9 analysts
$67.42
523.79% Upside
 +7.1%
NVO
Novo Nordisk
 Nov 29, 2018 HOLD Hold
+158.8% avg upside
26 analysts
$290.00
532.15% Upside
 +25.3%
🔒 31 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
David Evans — Frequently Asked Questions
How accurate are David Evans's stock ratings?
Based on the calls 13Foresight could measure, about 62% of David's ratings were profitable over a one-year hold, with an average return of +9.5% per rating, or +0.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is David ranked on 13Foresight?
David Evans is currently ranked #1007 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on GB:0QIU, CH:NOVN, DE:MRK, GB:GSK, GB:AZN, CH:ROP, GB:0NZT, FR:SAN, CH:ALC, FR:EAPI, GB:0G99, FR:VIRP and 24 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.